• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Electromed Inc.

    10/1/24 4:16:41 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ELMD alert in real time by email
    DEFA14A 1 elmd240999s1_defa14a.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

     

    PROXY STATEMENT PURSUANT TO SECTION 14(A) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Filed by the Registrant ☑

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☑Definitive Additional Materials
    ☐Soliciting Material Pursuant to §240.14a-12

     

    ELECTROMED, INC.

     

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

    ☑No fee required.
    ☐Fee paid previously with preliminary materials.
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    ELECTROMED, INC.

    500 SIXTH AVENUE NW 

    NEW PRAGUE, MN 56071

     

     

     

     

     

     

     

     

     

     

     

     

    V57114-P18401

     

     

     

     

    You invested in ELECTROMED, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on November 15, 2024.

     

    Get informed before you vote 

    View The Annual Report on Form 10-K and Notice and Proxy Statement and Shareholder Letter online OR you can receive a free paper or email copy of the material(s) by requesting prior to November 1, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

             
        For complete information and to vote, visit www.ProxyVote.com  
           
      Control #    
             

     

    Smartphone users

     

    Point your camera here and
    vote without entering a
    control number  

      Vote Virtually at the Meeting*
    November 15, 2024
    8:00 AM CST
     

     

    Virtually at:
    www.virtualshareholdermeeting.com/ELMD2024

       
       
       

      

    *Please check the meeting materials for any special requirements for meeting attendance.

     

     

     

     

    Vote at www.ProxyVote.com

     

     

     

    THIS IS NOT A VOTABLE BALLOT

     

    This is an overview of the proposals being presented at the
    upcoming shareholder meeting. Please follow the instructions on
    the reverse side to vote these important matters.

     

     

     

     

     

     

     

     

    Voting Items     Board
    Recommends
    1. Election of Directors, thereby setting the number of directors at eight.  
      Nominees:      
      01) James L. Cunniff 05) Kathleen S. Skarvan For
      02) Stan K. Erickson 06) Andrew J. Summers  
      03) Gregory J. Fluet 07) Kathleen A. Tune  
      04) Joseph L. Galatowitsch 08) Andrea M. Walsh  
         
    2. To ratify appointment of RSM US LLP as our independent registered public accounting firm. For
    3. To approve, on a non-binding and advisory basis, our executive compensation. For
    NOTE: At their discretion, the proxies are authorized to vote on any other business properly brought before the meeting or any adjournment thereof.  

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V57115-P18401  

     

     

    Get the next $ELMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELMD

    DatePrice TargetRatingAnalyst
    8/27/2025$36.00Buy
    Lake Street
    7/22/2025$29.00Buy
    Roth Capital
    2/20/2025$38.00Buy
    B. Riley Securities
    More analyst ratings

    $ELMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tune Kathleen A was granted 3,000 shares, increasing direct ownership by 25% to 15,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:16:07 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Erickson Stan K. was granted 3,000 shares, increasing direct ownership by 8% to 38,817 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:12:20 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fluet Gregory was granted 3,000 shares, increasing direct ownership by 17% to 21,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:11:51 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live webcast of the call will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electrome

    1/27/26 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on Electromed with a new price target

    Lake Street resumed coverage of Electromed with a rating of Buy and set a new price target of $36.00

    8/27/25 8:41:37 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital initiated coverage on Electromed with a new price target

    Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00

    7/22/25 7:52:34 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Electromed with a new price target

    B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00

    2/20/25 7:01:40 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cunniff James L. bought $137,250 worth of shares (9,000 units at $15.25), increasing direct ownership by 900% to 10,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    3/5/24 4:49:02 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Summers Andrew bought $302,368 worth of shares (28,797 units at $10.50) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/18/23 4:44:26 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cunniff James L. bought $10,560 worth of shares (1,000 units at $10.56) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    11/22/23 4:01:43 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    SEC Filings

    View All

    Electromed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Electromed, Inc. (0001488917) (Filer)

    12/18/25 4:46:08 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Electromed, Inc. (0001488917) (Filer)

    11/18/25 4:17:35 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Electromed Inc.

    10-Q - Electromed, Inc. (0001488917) (Filer)

    11/12/25 4:11:47 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Financials

    Live finance-specific insights

    View All

    Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live webcast of the call will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electrome

    1/27/26 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Leadership Updates

    Live Leadership Updates

    View All

    Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off

    5/27/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

    Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing

    10/28/24 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Names Jim Cunniff as President and Chief Executive Officer

    Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle

    6/5/23 8:15:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Electromed Inc.

    SC 13D/A - Electromed, Inc. (0001488917) (Subject)

    11/21/24 4:09:11 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/13/24 5:42:25 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/12/24 4:09:16 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care